Relief Therapeutics Aktie
| 2,98CHF | -0,23CHF | -7,02% | 
WKN DE: A3EFB5 / ISIN: CH1251125998
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 0 | 0 | 0 | 0 | 31 | 
| Umsatz pro Mitarbeiter in Mio. EUR | 0,00 | 0,00 | 0,00 | 0,00 | 0,27 | 
Bilanz (in Mio. CHF) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 47 | 55 | 23 | 18 | 18 | 
| Summe Anlagevermögen | 31 | 197 | 166 | 58 | 35 | 
| Summe Aktiva | 78 | 252 | 189 | 76 | 53 | 
Bilanz (in Mio. CHF) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 11 | 70 | 43 | 24 | 17 | 
| Summe Eigenkapital | 67 | 182 | 145 | 52 | 37 | 
| Summe Passiva | 78 | 252 | 189 | 76 | 53 | 
Adresse
| Avenue de Sécheron 15, 1202 Geneva | |
| Telefon | +41 (22) 545-11-16 | 
| Internet | http://www.relieftherapeutics.com | 
Management
| 
						Giorgio Reiner
						 Chief Scientific Officer  | 
				
| 
						Gregory A. Van Beek
						 Director  | 
				
| 
						Jeremy Meinen
						 Chief Financial Officer & Treasurer  | 
				
| 
						Paolo Galfetti
						 Chief Business Officer  | 
				
| 
						Peter Egon de Svastich
						 Director  | 
				
| 
						Raghuram Selvaraju
						 Chairman  | 
				
| 
						Tommy Elzinga
						 Director  | 
				
| 
						Vincenzo Gallo
						 Head-Legal & Compliance  |